- Merck & Co Inc MRK is voluntarily recalling one lot of Cubicin (daptomycin for injection) 500 mg with expiry June 2022.
- Approximately 22,000 vials will be affected by this recall.
- The recall was initiated after a customer complaint reported that a glass piece was found in a vial of Cubicin after reconstitution.
- If used by the patient, local irritation or swelling at the infusion site may occur. More serious potential outcomes include blockage and clotting in blood vessels, life-threatening if a critical organ is affected.
- Other clinical consequences could include prolonged hospitalization.
- Cubicin is a lipopeptide antibacterial indicated for complicated skin and skin structure infections (cSSSI) in adult and pediatric patients.
- Price Action: MRK shares are up 0.40% at $79.81 during the premarket session on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
